GentiBio is a startup founded in 2018 based in Israel. Brouky records 1 investor associated with the company.
GentiBio is a clinical-stage biotechnology company that engineers regulatory T cells (EngTregs) to develop therapies for autoimmune and acute inflammatory diseases, including programs targeting Type 1 diabetes.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.